🚨It’s monday & we have another FDA approval
👉FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
👉Read our paper just published in Cell Press Journal Trends in Cancer on “Tumor-agnostic drug development in dMMR/MSI-H solid tumors”.
Link to paper: Click here
👉Link to FDA approval in tumor specific endometrial context: Click here
Source: Vivek Subbiah / Linkedin